Welcome to Greenshoots.
Greenshoots is a collection of fresh intellectual property insight, analysis and commentary on the issues that matter most to those who invent, manage and protect intellectual property, written by the IP specialists of Appleyard Lees.
Now that you’re here, why not take a look around?
Tech transfer teams’ IP challenges post-COVID-19 and beyond: part four, pre-filing searches – good investment or waste of money?
In part four of the series, we discuss ‘Pre-filing searches – good investment or waste
No sign of reduced remittal in opposition appeal proceedings – the ‘ping-pong’ carries on
A year on, and there is no sign of reduced remittal in opposition appeal proceedings.
From Snail Mail to Streaming: The Netflix IP Story
Many of us are familiar with binge-watching TV series on Netflix, but few of us are familiar with Netflix’s vast intellectual property (IP) portfolio. We take a look at Netflix’s IP story in this article, which contains as many twists and turns as one of its original dramas.
IP litigation in a pandemic – going digital?
This article explains how court proceedings in England and Wales can be conducted digitally and considers how the pandemic may result in permanent changes to working practices going forwards.
The Greenshoots Podcast by Appleyard Lees, Episode 13: the intellectual property story behind vaccines & other health innovation.
What’s behind the headlines and soundbites? Patent attorneys Richard Bray, Barbara Fleck and Kate Hickinson
Developing and patenting ‘green’ chemical innovation: drivers, trends, considerations, growth areas
There are many sectors in which companies are inventing and patenting green technologies. In the chemical field, there is considerable activity in relation to carbon dioxide gas reduction, developing sustainable non-polluting processes and using alternatives to fossil fuels.
The Greenshoots Podcast, Episode 12: the effect of the pandemic and lockdown on IP and innovation, seven months on
Appleyard Lees partners and patent attorneys Adam Tindall and Richard Bray look back at the first episode of The Greenshoots Podcast, recorded in April 2020, at the start of the pandemic.
Tech transfer teams’ IP challenges post-COVID-19 and beyond: part three how much data is enough in biotech and pharma patents applications?
‘Tech transfer teams’ IP challenges post-COVID-19 and beyond’ is a series of interactive virtual discussions,
Reduced patent fees for businesses qualifying as small or micro entities – a discussion of requirements, benefits and risk in Canada, Japan and the U.S.
Pursuing patent protection in multiple countries can be expensive. Whilst cost is always important, for some small companies, reducing expenditure is currently paramount to survival during the enforced global slowdown.
